MPO and interstitial lung disease: Taken together, these findings suggest that clinicians should create a decision-making strategy for the treatment of MPO-ANCA-positive ILD with an awareness of the presence of these four major causes of death (i.e., AE of ILD, PF-ILD, infectious disease, and DAH).